^
    almost3years
    Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study. (PubMed, Mol Oncol)
    In conclusions, ctDNA detection at baseline was associated with shorter PFS in patients included in the TAKTIC trial. Plasma-based copy number analysis may help to identify alterations involved in resistance to treatment.
    P1/2 data • Journal • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • RPS6 (Ribosomal Protein S6)
    |
    TP53 mutation • HER-2 negative • AKT1 mutation
    |
    paclitaxel • LY2780301
    3years
    TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. (PubMed, Eur J Cancer)
    Combining LY2780301 and weekly paclitaxel in patients with HER2-negative ABC was feasible with preliminary evidence of efficacy in both the overall population and the PI3KAKT+ subgroup.
    Clinical • P1/2 data • Clinical Trial,Phase I • Clinical Trial,Phase II • Journal • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • RPS6 (Ribosomal Protein S6)
    |
    HER-2 negative
    |
    paclitaxel • LY2780301